亚太遗传性视网膜疾病市场 – 行业趋势及 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

亚太遗传性视网膜疾病市场 – 行业趋势及 2029 年预测

  • Pharmaceutical
  • Published Report
  • Mar 2022
  • Asia-Pacific
  • 350 页面
  • 桌子數: 189
  • 图号: 37

>亚太遗传性视网膜疾病市场,按疾病类型(视网膜色素变性、斯塔加特病、全色盲、视锥杆营养不良、脉络膜缺失、莱伯先天性黑蒙、黄斑水肿等)、类型(诊断和治疗)、最终用户(医院、专科诊所、门诊手术中心、家庭医疗保健等)、分销渠道(零售销售和直接招标)划分,行业趋势及预测至 2029 年。

亚太遗传性视网膜疾病市场

市场分析与洞察:亚太地区遗传性视网膜疾病市场

遗传性视网膜疾病(IRD)是一组可能导致严重视力丧失甚至失明的疾病。每个 IRD 都由至少一个基因无法正常工作引起。IRD 会影响所有年龄段的人,进展速度不同,而且很少见。然而,许多 IRD 是退行性的,这意味着疾病的症状会随着时间的推移而恶化。常见的 IRD 类型包括莱伯先天性黑蒙 (LCA)、视网膜色素变性、脉络膜白斑、斯塔加特病和全色盲。基因治疗的目标是纠正或补偿有缺陷的基因。由于视网膜具有独特的物理构造,IRD 是基因治疗的特别有力的候选者。与身体的其他器官相比,眼睛很小,易于进行治疗。然而,身体的某些部位具有免疫特权,这意味着正常的免疫反应不那么活跃。这通常发生在我们身体非常重要的部位,如果出现肿胀或炎症,可能会受损。这意味着植入眼睛的任何东西(例如带有修正基因的细胞)都不太可能被排斥。

遗传性视网膜疾病的诊断和治疗包括各种技术,这些技术允许在产品批准后诊断遗传性视网膜疾病。该疾病的治疗方法最近已获批准,这支持了市场的增长。

遗传性视网膜疾病具有支持作用,旨在减少疾病的进展。Data Bridge Market Research 分析,遗传性视网膜疾病市场在 2022 年至 2029 年的预测期内将以 6.8% 的复合年增长率增长。

报告指标

细节

预测期

2022 至 2029 年

基准年

2021

历史岁月

2020(可定制至 2019 - 2014)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

疾病类型(视网膜色素变性、斯塔加特病、全色盲、视锥细胞-视杆细胞营养不良、脉络膜缺失、莱伯先天性黑蒙、黄斑水肿等)、按类型(诊断和治疗)、最终用户(医院、专科诊所、门诊手术中心、家庭医疗保健等)、分销渠道(零售和直接招标)

覆盖国家

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)

Market Players Covered

Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson,  IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies

Inherited Retinal Diseases Market Dynamics

Drivers

  • Increase in the Prevalence of Inherited Retinal Diseases

The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000, affecting two million people online.

  • Increasing in Pipeline Products

As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the Asia-Pacific inherited retinal diseases market.High prevalence of genetic conditions

Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of the inherited retinal diseases market.

Furthermore, an increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness, and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as an increase in the demand for effective therapies and a rising adoption rate for early genetic counseling will positively impact the growth rate of the inherited retinal diseases market. Additionally, high disposable income, rising number of cases of  various retinal diseases will result in the expansion of inherited retinal diseases market. 

Opportunities

  • Increase in Government Initiatives Towards Inherited Retinal Disease.

Moreover, the increase in awareness and treatment seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, the high unmet need for current treatment and developments in healthcare technology will escalate the growth rate of the inherited retinal diseases market in the future.

Restraints/Challenges

However, the high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of the inherited retinal diseases market. Additionally, lack of enough qualified professionals and complications involved with the disease will hinder the inherited retinal diseases market growth.

This inherited retinal diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Inherited retinal diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Inherited retinal disease is a genetic disorder that is relatively uncommon and whose incidence is unknown. According to a study of inherited retinal diseases the prevalence of IRD’s is 1 in 3000.

Retinitis pigmentosa is the most common disorder among the other disorders. Retinitis pigmentosa is a group of related eye disorders caused by variations in 60 genes that affect the retina. IRDs are a heterogeneous group of orphan eye diseases with a prevalence estimated at between 5 to 10%, with a Asia-Pacific IRD caseload in the range of 5–10 million individuals.

Inherited retinal diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Post COVID-19 Impact on Inherited Retinal Diseases Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

  • In January 2022, Australian Healthcare agency HSA has aaproved the Luxturna therapy for inherited retinal diseases. This will increase the revenue for the companies in the market share.

亚太遗传性视网膜疾病市场

Asia-Pacific Inherited Retinal Diseases Market Scope

The inherited retinal diseases market is segmented into disease type, type, end-user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Disease Type

  • Retinitis Pigmentosa
  •  Stargardt’s Disease 
  •  Achromatopsia
  •  Cone-Rod Dystrophy
  •  Choroideremia
  •  Leber Congenital Amaurosis (LCA)  
  •  Macular Edema
  •  Others

On the basis of type, the Inherited Retinal Diseasesmarket is segmented into disease type (retinitis pigmentosa, stargardt’s disease, achromatopsia, cone-rod dystrophy, choroideremia, leber congenital amaurosis, macular edema, and others), by type (diagnosis and therapy), end-users (hospitals, specialty clinics, ambulatory surgical centers, home healthcare, others), distribution channel (retail sales and direct tender.

Type

  • Diagnosis
  • Therapy

On the basis of type, the inherited retinal diseases market is segmented into diagnosis and therapy. The diagnosis segment is sub-segmented into gene therapy, retinal prosthetic, neuroprotective agents, others. The neuroprotective agents are further sub-segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, others. The diagnosis segment is segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further sub-segmented into retinal imaging, electrophysiological tests, visual field test and clinical eye examination. Retinal imaging is further segmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO), adaptive optics (AO) imaging and conventional color fundus imaging. Electrophysiological tests are further segmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Visual field test is further segmented into computerized visual field tests and manual field test. Clinical Eye examination is segmented into slit lamp, indirect ophthalmoscopy, refraction test, dilation exam

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory surgical center
  • Home Healthcare
  • Others

On the basis of end-users, the inherited retinal diseases market is segmented into hopsitals, specialty clinics, ambulatory surgical center, home healthcare and others

Distribution Channel

  • Retail Sales
  • Direct Tender

The inherited retinal diseases market is also segmented on the basis of distribution channel into retail sales, direct tender.

Pipeline Analysis

The pipeline analysis of inherited retinal diseases drugs includes various pipeline therapies such as NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd are involved in the development of potential drugs for the improvement of treatment of seizures.

Inherited Retinal Diseases Market Regional Analysis/Insights

The inherited retinal diseases market is analysed and market size insights and trends are provided by country, disease type, type, end-user and distribution channel as referenced above.

The countries covered in the inherited retinal diseases market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC).

China dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Inherited Retinal Diseases Market Share Analysis

The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.

遗传性视网膜疾病市场的一些主要参与者包括 Spark Therapeutics、Novartis AG、Okuvision、Nidek Co. Ltd.、Invitae Corporation、Carl Zeiss Meditech AG、Optos(尼康公司的子公司)、Neurosoft、PIXIUM VISION、LKC TECHNOLOGIES, INC.、Renurone、Astellas Pharma、REGENXBIO Inc.、Ionis Pharmaceutics、Sparing Vision、Ocugen Inc、Johnson & Johnson、IVERIC bio、Second Sight、Coave Therapeutics、MeiraGTx Limited、Gensight Biologics、ProQR Therapeutics、Bionic Vision Technologies 等。

研究方法:亚太地区遗传性视网膜疾病市场

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量,涉及数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区和供应商份额分析。如有进一步询问,请要求分析师致电。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC INHERITED RETINAL DISEASES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS FOR ASIA PACIFIC INHERITED RETINAL DISEASES MARKET

5 REGULATORY FRAMEWORK

6 PREMIUM INSIGHTS

6.1 PESTEL ANALYSIS

6.2 POTER’S FIVE FORCES MODEL

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES

7.1.2 INCREASE IN PIPELINE PRODUCTS

7.1.3 INCREASING PRODUCT APPROVAL FOR INHERITED RETINAL DISEASES

7.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER

7.2 RESTRAINTS

7.2.1 HIGH COST OF TREATMENT AND PROCEDURES

7.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS

7.3 OPPORTUNITIES

7.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARDS INHERITED RETINAL DISEASES(IRDS)

7.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE

7.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT

7.4 CHALLENGES

7.4.1 RISKS ASSOCIATED WITH IRD SPECIFIC GENE THERAPY

7.4.2 LIMITED ACCESS TO TREATMENT

8 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE

8.1 OVERVIEW

8.2 RETINITIS PIGMENTOSA

8.3 STARGARDT’S DISEASE

8.4 ACHROMATOPSIA

8.5 CONE-ROD DYSTROPHY

8.6 CHOROIDEREMIA

8.7 LEBER CONGENITAL AMAUROSIS (LCA)

8.8 MACULAR EDEMA

8.9 OTHERS

9 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY TYPE

9.1 OVERVIEW

9.2 DIAGNOSIS

9.2.1 CLINICAL DIAGNOSIS

9.2.1.1 RETINAL IMAGING

9.2.1.1.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)

9.2.1.1.2 FUNDUS AUTOFLUORESCENCE IMAGING (FAF)

9.2.1.1.3 SCANNING LASER OPHTHALMOSCOPY (SLO)

9.2.1.1.4 ADAPTIVE OPTICS (AO) IMAGING

9.2.1.1.5 CONVENTIONAL COLOR FUNDUS IMAGING

9.2.1.2 ELECTROPHYSIOLOGICAL TESTS

9.2.1.2.1 FULL-FIELD ELECTRORETINOGRAM (ERG)

9.2.1.2.2 DARK ADAPTOMETRY (DA)

9.2.1.3 VISUAL FIELD TEST

9.2.1.3.1 COMPUTERIZED VISUAL FIELD TESTS

9.2.1.3.2 MANUAL FIELD TEST

9.2.1.4 CLINICAL EYE EXAMINATION

9.2.1.4.1 SLIT LAMP

9.2.1.4.2 INDIRECT OPHTHALMOSCOPY

9.2.1.4.3 REFRACTION TEST

9.2.1.4.4 DILATION EXAM

9.2.1.5 OTHERS

9.2.2 GENETIC DIAGNOSIS

9.3 THERAPY

9.3.1 GENE THERAPY

9.3.2 RETINAL PROSTHETIC

9.3.3 NEUROPROTECTIVE AGENTS

9.3.3.1 VITAMIN A PALMITATE

9.3.3.2 DOCOSAHEXAENOIC ACID

9.3.3.3 LUTEIN

9.3.3.4 OTHERS

9.3.4 OTHERS

10 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 SPECIALTY CLINICS

10.4 AMBULATORY SURGICAL CENTERS

10.5 HOME HEALTHCARE

10.6 OTHERS

11 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 RETAIL SALES

11.2.1 HOSPITAL PHARMACIES

11.2.2 RETAIL PHARMACIES

11.2.3 OTHERS

11.3 DIRECT TENDER

12 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY REGION

12.1 ASIA-PACIFIC

12.1.1 CHINA

12.1.2 JAPAN

12.1.3 INDIA

12.1.4 SOUTH KOREA

12.1.5 AUSTRALIA

12.1.6 SINGAPORE

12.1.7 THAILAND

12.1.8 INDONESIA

12.1.9 PHILIPPINES

12.1.10 MALAYSIA

12.1.11 VIETNAM

12.1.12 REST OF ASIA-PACIFIC

13 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 SPARK THERAPEUTICS, INC.

15.1.1 COMPANY SNAPSHOT

15.1.2 COMPANY SHARE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENTS

15.1.4.1 PROGRAM LAUNCH

15.1.4.2 ACQUISITIONS

15.2 NOVARTIS AG

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.2.5.1 AGREEMENT

15.3 OKUVISION

15.3.1 COMPANY SNAPSHOT

15.3.2 COMPANY SHARE ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENTS

15.3.4.1 EXPANSION

15.3.4.2 EVENTS

15.3.4.3 APPROVAL

15.4 NIDEK CO., LTD

15.4.1 COMPANY SNAPSHOT

15.4.2 COMPANY SHARE ANALYSIS

15.4.3 PRODUCT PORTFOLIO

15.4.4 RECENT DEVELOPMENTS

15.4.4.1 PRODUCT LAUNCH

15.4.4.2 PRODUCT LAUNCH

15.5 INVITAE CORPORATION

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENTS

15.5.5.1 PROGRAM LAUNCH

15.5.5.2 ACQUISITION

15.6 ZEISS INTERNATIONAL

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENTS

15.6.4.1 EVENTS

15.6.4.2 SOCIAL INVOLVEMENT

15.7 OPTOS (A SUBSIDIARY OF NIKON CORPORATION)

15.7.1 COMPANY SNAPSHOT

15.7.2 REVENUE ANALYSIS

15.7.3 PRODUCT PORTFOLIO

15.7.4 RECENT DEVELOPMENTS

15.8 NEUROSOFT

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 ASTELLAS PHARMA INC.

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.1 BIONIC VISION TECHNOLOGIES

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.10.3.1 AWARD

15.11 COAVE THERAPEUTICS

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.11.3.1 AGREEMENT

15.12 GENSIGHT BIOLOGICS

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENTS

15.12.4.1 EVENT

15.12.4.2 AWARD

15.13 IONIS PHARMACEUTICALS

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENT

15.13.4.1 EVENT

15.14 IVERIC BIO

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENTS

15.15 JOHNSON &JOHNSON SERVICES, INC.

15.15.1 COMPANY SNAPSHOT

15.15.2 REVENUE ANALYSIS

15.15.3 PRODUCT PORTFOLIO

15.15.4 RECENT DEVELOPMENT

15.15.4.1 COLLABORATION

15.16 LKC TECHNOLOGIES, INC.

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.16.3.1 PRODUCT LAUNCH

15.17 MEIRAGTX LIMITED

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENTS

15.17.3.1 EVENTS

15.17.3.2 AWARD

15.17.3.3 COLLABORATION

15.18 OCUGEN INC.

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENTS

15.18.3.1 INVESTMENT

15.18.3.2 CLINICAL TRIAL

15.19 PIXIUM VISION

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENT

15.19.4.1 AWARD

15.2 PROQR THERAPEUTICS

15.20.1 COMPANY SNAPSHOT

15.20.2 PRODUCT PORTFOLIO

15.20.3 RECENT DEVELOPMENT

15.20.3.1 EVENT

15.21 SECOND SIGHT

15.21.1 COMPANY SNAPSHOT

15.21.2 PRODUCT PORTFOLIO

15.21.3 RECENT DEVELOPMENT

15.21.3.1 PRODUCT LAUNCH

15.22 SPARING VISION

15.22.1 COMPANY SNAPSHOT

15.22.2 PRODUCT PORTFOLIO

15.22.3 RECENT DEVELOPMENT

15.22.3.1 ACQUISITION

15.23 REGENXBIO INC.

15.23.1 COMPANY SNAPSHOT

15.23.2 PRODUCT PORTFOLIO

15.23.3 RECENT DEVELOPMENTS

15.23.3.1 EVENT

15.23.3.2 COLLABORATION

15.23.3.3 CERTIFICATION

15.24 RENEURON GROUP PLC

15.24.1 COMPANY SNAPSHOT

15.24.2 PRODUCT PORTFOLIO

15.24.3 RECENT DEVELOPMENT

15.24.3.1 STRATEGIC INITIATIVE

16 QUESTIONNAIRE

17 RELATED REPORTS

表格列表

TABLE 1 PIPELINE ANALYSIS FOR INHERITED RETINAL DISEASES:

TABLE 2 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC RETINITIS PIGMENTOSA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC STARGARDT’S DISEASE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC ACHROMATOPSIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC CONE-ROD DYSTROPHY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC CHOROIDERMIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS (LCA) IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC MACULAR EDEMA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC ELECTROPHYSIOLOGICAL TETS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC THERAPY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC HOSPITALS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC SPECIALTY CLINICS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC HOME HEALTHCARE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC DIRECT TENDER IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 33 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 34 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 ASIA-PACIFIC THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 ASIA-PACIFIC NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 ASIA-PACIFIC DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 ASIA-PACIFIC CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 ASIA-PACIFIC RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 ASIA-PACIFIC ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 ASIA-PACIFIC VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 ASIA-PACIFIC CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 ASIA-PACIFIC RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 46 CHINA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 47 CHINA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 CHINA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 CHINA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 CHINA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 CHINA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 CHINA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 CHINA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 CHINA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 CHINA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 CHINA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 57 CHINA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 58 CHINA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 JAPAN INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 60 JAPAN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 JAPAN THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 JAPAN NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 JAPAN DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 JAPAN CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 JAPAN RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 JAPAN ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 JAPAN VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 JAPAN CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 JAPAN INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 JAPAN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 JAPAN RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 INDIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 73 INDIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 INDIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 INDIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 INDIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 INDIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 INDIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 INDIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 INDIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 INDIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 INDIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 83 INDIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 INDIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 85 SOUTH KOREA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 86 SOUTH KOREA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 SOUTH KOREA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 88 SOUTH KOREA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 SOUTH KOREA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 SOUTH KOREA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 SOUTH KOREA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 SOUTH KOREA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 SOUTH KOREA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 SOUTH KOREA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 SOUTH KOREA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 SOUTH KOREA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 SOUTH KOREA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 98 AUSTRALIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 99 AUSTRALIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 AUSTRALIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 101 AUSTRALIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 AUSTRALIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 AUSTRALIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 AUSTRALIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 AUSTRALIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 AUSTRALIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 AUSTRALIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 AUSTRALIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 109 AUSTRALIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 110 AUSTRALIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 111 SINGAPORE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 112 SINGAPORE INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 113 SINGAPORE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 SINGAPORE NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 SINGAPORE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 SINGAPORE CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 SINGAPORE RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 SINGAPORE ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 SINGAPORE VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 SINGAPORE CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 SINGAPORE INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 122 SINGAPORE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 123 SINGAPORE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 124 THAILAND INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 125 THAILAND INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 126 THAILAND THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 127 THAILAND NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 THAILAND DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 THAILAND CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 THAILAND RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 131 THAILAND ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 132 THAILAND VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 133 THAILAND CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 THAILAND INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 135 THAILAND INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 136 THAILAND RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 137 INDONESIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 138 INDONESIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 139 INDONESIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 INDONESIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 141 INDONESIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 INDONESIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 143 INDONESIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 INDONESIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 INDONESIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 146 INDONESIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 147 INDONESIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 148 INDONESIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 149 INDONESIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 150 PHILIPPINES INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 151 PHILIPPINES INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 152 PHILIPPINES THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 153 PHILIPPINES NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 154 PHILIPPINES DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 155 PHILIPPINES CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 156 PHILIPPINES RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 157 PHILIPPINES ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 158 PHILIPPINES VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 159 PHILIPPINES CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 PHILIPPINES INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 161 PHILIPPINES INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 162 PHILIPPINES RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 163 MALAYSIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 164 MALAYSIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 165 MALAYSIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 166 MALAYSIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 167 MALAYSIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 168 MALAYSIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 169 MALAYSIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 170 MALAYSIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 171 MALAYSIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 MALAYSIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 173 MALAYSIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 174 MALAYSIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 175 MALAYSIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 176 VIETNAM INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 177 VIETNAM INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 VIETNAM THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 179 VIETNAM NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 180 VIETNAM DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 181 VIETNAM CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 182 VIETNAM RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 183 VIETNAM ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 184 VIETNAM VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 185 VIETNAM CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 186 VIETNAM INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 187 VIETNAM INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 188 VIETNAM RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 189 REST OF ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN ASIA PACIFIC INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE ASIA PACIFIC INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 RETINITIS PIGMENTOSA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC INHERITED RETINAL DISEASES MARKET IN 2022 & 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC INHERITED RETINAL DISEASES MARKET

FIGURE 16 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2021

FIGURE 17 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2020-2029 (USD MILLION)

FIGURE 18 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 19 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 20 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY TYPE, 2021

FIGURE 21 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY TYPE, 2020-2029 (USD MILLION)

FIGURE 22 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 23 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY END USER, 2021

FIGURE 25 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 26 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY END USER, CAGR (2022-2029)

FIGURE 27 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY END USER, LIFELINE CURVE

FIGURE 28 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 29 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 30 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 31 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: SNAPSHOT (2021)

FIGURE 33 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021)

FIGURE 34 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 35 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 36 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 37 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Asia-Pacific Inherited Retinal Diseases Market will be projected to grow at a CAGR of 6.8% during the forecast period of 2022 to 2029.
The increasing prevalence and continuous discovery of new mutagenic sites, & the increase in the prevalence rate of some genetic conditions flourishing the growth of the Asia-Pacific Inherited Retinal Diseases Market.
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC) are the Countries Covered in Asia-Pacific Inherited Retinal Diseases Market.
The major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.